Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm study of RIST4721 in active familial Mediterranean fever despite colchicine
MOH_2022-07-07_011894Phase 2Completed
- Sponsor
- Aristea Therapeutics
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vimnerixin in Familial Mediterranean fever (FMF), sponsored by Aristea Therapeutics. Primary endpoint: Safety of RIST4721. Started Jun 2022; status: completed.
02
Drugs
vimnerixin
03
Conditions
Familial Mediterranean fever (FMF)
Beyond the preview
Go deeper on MOH_2022-07-07_011894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-07_011894.